UK Stocks-Factors to watch on March 28
Reuters · 1d ago
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
NASDAQ · 1d ago
Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study
NASDAQ · 1d ago
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
Benzinga · 1d ago
BRIEF-Eplontersen Demonstrated Sustained Benefit In Phase III Trial For Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Through 66 Weeks
Reuters · 1d ago
US STOCKS-Wall St set for higher open as SVB deal soothes frayed nerves
Reuters · 1d ago
Ionis, AstraZeneca report positive outcomes from eplontersen trial
Seeking Alpha · 2d ago
US stock futures climb as banking crisis fears ebb after SVB deal
NASDAQ · 2d ago
US STOCKS-Futures climb as banking crisis fears ebb after SVB deal
Reuters · 2d ago
UPDATE 1-UK stocks start the week higher as banks, AstraZeneca climb
Reuters · 2d ago
Ionis Pharma' Phase 3 NEURO-TTRansform Study Of Eplontersen For Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Met Co-primary Endpoints Demonstrating A Sustained Reduction In TTR And Benefits In Neuropathy Through 66 Weeks
Benzinga · 2d ago
Ionis Pharma Reports Positive 66-week Results Of Eplontersen Phase 3 Study In ATTRv-PN
NASDAQ · 2d ago
AstraZeneca Says Phase 3 Trial of Eplontersen Drug Met Co-Primary Endpoints
AstraZeneca Says Phase 3 Trial of Eplontersen Drug Met Co-Primary Endpoints
MT Newswires · 2d ago
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
NASDAQ · 4d ago
FDA draft guidance impacts companies using accelerated approval for oncology drugs
Seeking Alpha · 4d ago
BOE: Discounted Global Covered Call Fund
Seeking Alpha · 5d ago
White House seeking alternative supply chains for pharmaceutical ingredients
Seeking Alpha · 5d ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
NASDAQ · 5d ago
AstraZeneca's blood cancer drug Calquence gets conditional approval in China
Seeking Alpha · 6d ago
3 Exceptionally Safe Dividend Stocks That Can Turn $400,000 Into $1 Million by 2030
NASDAQ · 6d ago
Webull provides a variety of real-time AZN stock news. You can receive the latest news about Astrazeneca Plc through multiple platforms. This information may help you make smarter investment decisions.
About AZN
AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in various stages of clinical development. Its pipeline includes the Alexion Rare Disease portfolio and comprises approximately 179 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. Its geographical segments include United Kingdom, Rest of Europe, The Americas and Asia, Africa & Australasia. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies.